76 results about "NERVOUS DISORDERS" patented technology

The invention relates to the technical field of medical informatics, in particular to an ADL ability training data management system based on neurological disease patients. The system comprises a memory and a processor, and the processor executes computer programs stored in the memory so as to realize the following steps: acquiring attitude images and scales of normal personnel and neurological disease patients in the ADL ability training process; according to the position difference, the depth difference and the time difference between the joint points in the to-be-evaluated image and the joint points in the reference image, evaluating the possibility value that the to-be-evaluated image and the reference image are in the same action, and screening a contrast image; synthesizing the possibility value that the to-be-evaluated image and all the contrast images are in the same action and the acquisition time of the to-be-evaluated image to obtain a motion completion index; and determining an effective evaluation value of training according to the difference between the change characteristics of each type of indexes of the neurological disease patient at each moment and other indexes and each type of indexes. According to the invention, an accurate comprehensive result of ADL capability training data can be obtained.

The invention discloses a neural disease diagnosis system based on space-time attention and dynamic field self-adaption. The method belongs to the technical field of cross-modal medical data adaptive analysis. The technical problem that a brand new system capable of simultaneously fusing multi-modal information and modeling multi-scale spatial-temporal features and having dynamic field adaptive ability is urgently needed to improve the accuracy and generalization ability of intelligent diagnosis of multi-site nerve diseases is solved. The system comprises a data preprocessing module for extracting a standardized time sequence of a brain region from fMRI time sequence data; the two-channel feature coding network module obtains global features through an attention mechanism; according to the feature fusion and classification module, a main task classifier executes a main task and predicts whether a to-be-tested person suffers from nerve diseases or not, and a domain task classifier executes a domain task and predicts a site to which the to-be-tested person belongs; and the dynamic balance training module adjusts the dynamic balance of the main task and the domain task through a dynamic balance control strategy.

The present invention relates to: a sustained-release injectable composition for treating or preventing neurological disorders; and a method for preparing same. The sustained-release injectable composition uses microparticles containing cannabidiol and continuously releases the cannabidiol for at least one month, and thus can be effective in treating or preventing neurological disorders. In addition, the sustained-release injectable composition includes cannabidiol, which is non-toxic and can be used continuously for a long time due to the absence of side effects from long-term use, and thus can exhibit a therapeutic or prophylactic effect on neurological disorder patients for at least one month through a single injection. Therefore, the sustained-release injectable composition can greatly improve the convenience of administration.

The present disclosure relates to a method and a system for detecting a neurological disease and an eye gaze-pattern abnormality related to the neurological disease of a user. The method comprises displaying stimulus videos on a screen of an electronic device and simultaneously filming with a camera of the electronic device to generate a video of the user's face for each one of the stimulus videos, each one of the stimulus videos corresponding to a task. The method further comprises providing a machine learning model for gaze predictions, generating the gaze predictions for each video frame of the recorded video, and determining features for each task to detect the neurological disease using a pre-trained machine learning model.

A method comprising to analyze the captured video data of the patient's body parts and to generate patient motion metrics, patient posture metrics, and patient gait metrics for each exercise routine completed by the patient based on the analyzed video data; store, in a database, the generated patient motion metrics, the patient posture metrics and the patient gait metrics for each of the completed exercise routines, wherein the generated patient motion metrics, the generated patient posture metrics and the generated patient gait metrics are used to track patient progress during physical therapy sessions, diagnose movement disorders, and provide personalized, data-driven treatment plans to enhance immediate outcomes and long-term recovery with respect to the musculoskeletal and neurological disorders; apply motion amplification algorithms to enhance the additional video data to provide clarity of tremor movements; apply edge detection to enhance tremor movement boundaries and detection; generate tremor amplitude measurements and tremor frequency measurements based on the motion amplification and edge detection algorithms; and store, in the database, the generated tremor amplitude measurements and tremor frequency measurements, wherein the generated tremor amplitude measurements and tremor frequency measurements are analyzed for diagnosis and monitoring of disorders such as Parkinson's disease and Essential Tremor.

The present application relates to the technical field of postoperative rehabilitation, in particular to a postoperative rehabilitation intervention system for patients with neurological diseases based on evidence-based medical evidence. The steps implemented by the system include: obtaining characteristic data of a patient with a neurological disease to be analyzed and reference patients, a rehabilitation scheme of the reference patients and a postoperative Barthel index, calculating a reference factor of the reference patients corresponding to each rehabilitation scheme under each preoperative state; obtaining a comprehensive Barthel index of each rehabilitation scheme under each preoperative state by using the reference factor and the postoperative Barthel index, determining a correction factor under each preoperative state according to the comprehensive Barthel index, and correcting the comprehensive Barthel index to obtain a target Barthel index; determining a reference rehabilitation scheme by combining the similarity of the characteristic data of the patient with a neurological disease to be analyzed and different reference patients and the target Barthel index. The present application can improve the postoperative rehabilitation intervention effect for patients with neurological diseases.

The present invention relates to nitrogen-containing heterocyclic compounds having a phenyl group and uses thereof. The compounds, according to the present invention, effectively enhance synaptic plasticity without side-effects and thus may exhibit treatment effects for various neurological disorders such as neurodegenerative disease, neurodegenerative pathology, neuropsychiatric disorder, amnesia, cognitive impairment / damage, and extinction learning disorder.

Self-emulsifying drug delivery compositions are provided for oral delivery of cannabinoids. The cannabinoids are dissolved in a solubilizer together with at least one stabilizer to improve dissolution and stability. The cannabinoids are also gelled in a standardized matrix to control the release upon contact with aqueous media. Also provided are methods comprising uses of oral cannabinoid compositions for the treatment of a neurological disease and / or disorder in a subject.

The present disclosure relates to the method of treating neurological disease in a recreational drug user by administering an effective amount of soticlestat or a pharmaceutically acceptable salt thereof, wherein the treatment does not produce the potential of drug abuse.

The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg / ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

To provide a drug having positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.SOLUTION: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons.SELECTED DRAWING: Figure 12

The present invention relates to salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharma-ceutically acceptable solvates thereof for use in the treatment and / or prevention of sensory neuron diseases.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

The invention provides an application of sialic acid in a product for enhancing resistance to external pressure, and provides a new application of sialic acid in food, health care products and medicines for promoting resistance to external pressure. Additional sialic acid is supplemented in the early development stage of the mouse, pressure resistance detection is carried out in the puberty, and the result shows that intake of sialic acid in the early life stage can enhance the external environment pressure resistance of the puberty mouse; according to the technical scheme, a new method and feasible reference can be provided for preventing related neurological diseases caused by external pressure.

The present invention relates to nitrogen-containing heterocyclic compound derivatives and uses thereof. The compounds according to the present invention can exert therapeutic effects on various neurological disorders, such as neurodegenerative diseases, neurodegenerative pathologies, neuropsychiatric disorders, memory loss, cognitive dysfunction / impairment, and impairment of extinction learning, by effectively enhancing synaptic plasticity without side effects.

The invention discloses a brain venation plexus vesicle segmentation method, and the method comprises the steps: firstly reinforcing the signal contrast of the whole venation plexus through a high-resolution T1 enhanced image, and then achieving the stable segmentation of vesicles through employing the two steps: the whole segmentation of the venation plexus and the segmentation of the vesicles. In the vesicle segmentation process, as the vesicles are filled with cerebrospinal fluid, the difference between a venation plexus entity (high signal) and the cerebrospinal fluid (low signal) in a T1 enhanced image is utilized, a vesicle segmentation reference threshold value is set, and vesicle voxel separation is realized through low-pass filtering. According to the method, the vesicle structure of the cerebral venation plexus can be segmented, the volume of the vesicle structure can be calculated, and the volume of the vesicle of the cerebral venation plexus can be used as an image marker for auxiliary diagnosis of nerve diseases such as Alzheimer's disease.

A compound represented by formula (I) or a tautomer, optical isomer, deuterated substance, oxynitride, solvate, pharmaceutically acceptable salt or prodrug thereof can be used in preparing a pharmaceutical composition. The compound or the pharmaceutical composition can be used in the preparation a drug for the prevention and / or treatment of cancer, tumors, viral infections, depression, neurological disorders, trauma, age-related cataracts, organ transplant rejection or autoimmune diseases.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with phenoxy or benzyloxy substituted psychoplastogens.

This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of or improving a pathology of a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder, or for enhancing neuroplasticity in a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder making use of the combinations, compositions and kits of this invention.

Disclosed herein are salts and solid state forms of psilocybin, including psilocybin HCl, and salts and solid forms of O-acetylpsilocin, including O-acetylpsilocin fumarate. Also disclosed are methods for making the salts and solid forms and methods for administering the salts and solid forms. The salts and solid forms disclosed herein are useful for treating neurological disease and / or a psychiatric disorder in a subject.

The present application discloses a gait analysis method, device, system, electronic device and storage medium. The gait analysis method includes: simultaneously acquiring the bioelectrical signals of a target object and dual-view synchronized videos during the movement of the target object; extracting gait parameters from the dual-view synchronized videos through a lightweight pose estimation network model; performing feature extraction on the bioelectrical signals to obtain bioelectrical signal feature parameters; and combining the gait parameters and the bioelectrical signal feature parameters to obtain a comprehensive gait analysis result. The gait analysis method provided by the embodiments of the present application acquires relatively comprehensive data, improves the calculation rate and reduces the analysis cost through a lightweight algorithm, and the gait analysis result obtained by combining bioelectrical signals and dual-view synchronized videos is relatively accurate, which can meet the requirements for the comprehensiveness of various types of data in current neurological disease research, realize the quantitative evaluation of neurological diseases, and promote the research progress of neurological diseases.

The invention relates to the technical field of data management, in particular to a neurology patient data management method and system, and the method comprises the following steps: carrying out the multi-source data collection of a neurology patient; performing data standardization preprocessing operation; the method comprises the following steps: performing preliminary division on neural disease subtypes by adopting fuzzy clustering and fuzzy logic rules, defining fuzzy boundaries among the subtypes, and outputting fuzzy feature data comprising subtype fuzzy membership degrees and related overlapping features; and performing stable identification on the subtype fuzzy boundary of the neurological disease of the patient, and outputting an intelligent analysis result including each subtype fuzzy classification result, membership information and overlapping region description. According to the method, the problem of unstable classification caused by fuzzy boundary of a traditional neural disease classification method is effectively solved, the misjudgment rate of a classification model is reduced, meanwhile, the adaptability of the model to patients with transition among subtypes is enhanced, and the clinical reliability and interpretability of classification are improved.

1. The name of the product of this design: head-mounted transcranial magnetic stimulator. 2. The purpose of this product design: to stimulate the frontal lobe neurons of the brain through the built-in electromagnetic block to emit electromagnetic waves to treat neurological diseases such as depression. 3. The design key point of this appearance design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

A method of activating heteromeric KCNQ2 / 3, KCNQ3 / 5, or KCNQ4 / 5 voltage-gated potassium channels in a cell membrane is described, as are compositions for use with same, as well as methods of reducing neuronal excitability and of ameliorating symptoms of epilepsy, anxiety, neuropathic pain, hypertension, cardiovascular disease, a neurodegenerative disorder, alcohol withdrawal, cancer, inflammation, or ophthalmic disease in a subject. These KCNQ2 / 3 (or KCNQ3 / 5 or KCNQ4 / 5) channels are heteromers that comprise KCNQ2 (or KCNQ5) subunits and KCNQ3 (or KCNQ4) subunits. In one embodiment, the method comprises: (a) contacting the cell membrane with a first agent that binds a KCNQ2 (or KCNQ5) subunit; and (b) contacting the cell membrane with a second agent that binds a KCNQ3 (or KCNQ4) subunit.

Provided herein are methods and compositions for prevention of, reduction of risk of, amelioration of, and / or treatment of neurological disorders, particularly neurological disorders characterized by neurodegeneration and / or neuroinflammation. In particular aspects, methods and / or compositions include means for transgenically overexpressing NFIA, SOX9, A2M, and / or MEGF10 in one or more populations of cells, such as astrocytes.

To provide novel cyclosporin derivatives.SOLUTION: Provided is a compound having the following structure or a pharmaceutically acceptable salt thereof. Also provided are a pharmaceutical composition comprising the same, and a method that uses the same for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, liver, and kidney diseases, and hair loss.SELECTED DRAWING: None

Provided are compositions comprising one or more polyunsaturated fatty acids or derivatives thereof, a phospholipid source, and optionally one or more additional emulsifiers, and methods of using same to treat various diseases. In some embodiments, provided are lymphatic-releasing compositions of eicosapentaenoic acid ethyl ester (LR-EtEPA) and methods of using same to increase EPA uptake in tissues and treat various diseases, including cardiopulmonary diseases, renal diseases, neurological diseases, and cancer.